Menu
Enrolling by invitation NCT07381816

GastroFlow: Investigation of the Gastrointestinal Blood Flow in Patients With Postprandial Hypotension

No phase Interventional Postprandial Hypotension Healthy Blood Flow

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: MRI + GIPR antagonist (Tool), MRI + hangrip, Saline and oral glucose.
Who it may be relevant to
Registry conditions: Postprandial Hypotension, Healthy, Blood Flow. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Denmark
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with postprandial hypotension.

Detailed description

Each participant will attend three independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2). Furthermore one day will be with handgrip exercise, without an infusion. Therefore the first two days are in randomized order.

MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines and pancreas.

Interventions

  • Other MRI + GIPR antagonist (Tool)
    GIP(3-30)NH2 infusion, oral glucose during MRI scans
  • Other MRI + hangrip
    Hangrip exercises, oral glucose during MRI scans
  • Other Saline and oral glucose
    Saline infusion oral glucose during MRI scans

Primary outcome measures

  • Blood flow [Time frame: 145 minutes]
Secondary outcome measures (2)
  • Blood flow [Time frame: 145 minutes]
  • Blood flow [Time frame: 145 minutes]

Eligibility criteria

For the PPH group

Inclusion criteria

  • Postprandial hypotension
  • Symptoms of postprandial hypotension

Exclusion criteria

  • Treatment with drugs that cannot be paused for 12 hours
  • Metallic implants that does not tolerate MRI
  • Any other disease or dysfunction that may disturb blood flow to the gut
  • Intake of more than 14 units of alcohol per week or abuse of drugs
  • Blood vessels that are not feasible for measuring flow in the MRI scanner
  • Low blood percent
  • Decreased kidney function
  • Decreased liver function
  • Claustrophobia

For the healthy group

Inclusion criteria

  • Matched by age, gender and BMI

Exclusion criteria

  • Postprandial hypotension
  • Metallic implants that does not tolerate MRI
  • Intake of more than 14 units of alcohol per week or abuse of drugs
  • Blood vessels that are not feasible for measuring flow in the MRI scanner
  • Low blood percent
  • Decreased kidney function
  • Decreased liver function
  • Claustrophobia
  • Autonomic dysfunction or other disease that cause changes in blood pressure during or after a meal
  • Intake of pharmaceutical products that influence the blood pressure

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Basic science

Study locations

Denmark · 1 center
  • Glostrup hospital — Glostrup Municipality

Identifiers

NCT: NCT07381816 · H-25007666 · NNF23OC0082437

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗